These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 37457564)

  • 1. Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO).
    Piaserico S; Riedl E; Pavlovsky L; Vender RB; Mert C; Tangsirisap N; Haustrup N; Gallo G; Schuster C; Brunner PM
    Front Med (Lausanne); 2023; 10():1185523. PubMed ID: 37457564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.
    Lynde C; Riedl E; Maul JT; Torres T; Pinter A; Fabbrocini G; Daniele F; Brnabic A; Reed C; Wilhelm S; Holzkämper T; Schuster C; Puig L
    Adv Ther; 2023 Mar; 40(3):869-886. PubMed ID: 36515803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
    Pinter A; Puig L; Schäkel K; Reich A; Zaheri S; Costanzo A; Tsai TF; Smith SD; Lynde C; Brnabic A; Reed C; Hill J; Schuster C; Riedl E; Paul C
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2087-2100. PubMed ID: 35766124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
    Armstrong A; González-Cantero A; Khattri S; Muzy G; Malatestinic WN; Lampropoulou A; Feely M; See SK; Mert C; Blauvelt A
    Dermatol Ther (Heidelb); 2024 Apr; 14(4):933-952. PubMed ID: 38521874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO.
    Riedl E; Pinter A; Zaheri S; Costanzo A; Brnabic A; Konicek B; McKenzie R; Lampropoulou A; Rayes ME; Haustrup N; Schuster C
    Dermatol Ther (Heidelb); 2024 May; 14(5):1327-1335. PubMed ID: 38649673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).
    Pinter A; Costanzo A; Khattri S; Smith SD; Carrascosa JM; Tada Y; Riedl E; Reich A; Brnabic A; Haustrup N; Lampropoulou A; Lipkovich I; Kadziola Z; Paul C; Schuster C
    Dermatol Ther (Heidelb); 2024 Jun; 14(6):1479-1493. PubMed ID: 38113010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO).
    Travaglini M; Maul JT; Kors C; Zaheri S; Gerwien J; Müller M; Brnabic A; Sabatino S; Schuster C; Tsai TF
    Clin Cosmet Investig Dermatol; 2023; 16():2971-2983. PubMed ID: 37881205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).
    Pinter A; Eyerich K; Costanzo A; Garrelts A; Schuster C; Mert C; Lampropoulou A; Fotiou K; Maul JT; Papp KA
    J Dermatolog Treat; 2024 Dec; 35(1):2350227. PubMed ID: 38797734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of ixekizumab for the treatment of moderate-to-severe plaque psoriasis with involvement of difficult-to-treat areas: A 52-week multicenter retrospective study.
    Valenti M; Gargiulo L; Ibba L; Cortese A; Toso F; Orsini D; Lora V; Frascione P; Sena P; Carugno A; Assorgi C; Costanzo A; Narcisi A
    J Dermatol; 2024 Jun; 51(6):839-843. PubMed ID: 38292002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study.
    Li Y; Lv C; Dang L; Lin B; Tao J; Zhang C; Zhou X; Ma H; Lu Y; Chen R; Li J; Dou G; Liang Y; Liang Y; Shi Y
    Dermatol Ther (Heidelb); 2024 Apr; 14(4):907-918. PubMed ID: 38536616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks.
    Reich A; Pinter A; Maul JT; Vender RB; Torres T; Brnabic A; Haustrup N; Reed C; Schuster C; Riedl E
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1825-1840. PubMed ID: 37147855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers.
    Orsini D; Gargiulo L; Ibba L; Cascio Ingurgio R; Valenti M; Perugini C; Pacifico A; Maramao FS; Frascione P; Costanzo A; Narcisi A
    J Dermatolog Treat; 2023 Dec; 34(1):2220849. PubMed ID: 37288760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
    Paller AS; Seyger MMB; Magariños GA; Pinter A; Cather JC; Rodriguez-Capriles C; Zhu D; Somani N; Garrelts A; Papp KA;
    JAMA Dermatol; 2022 May; 158(5):533-541. PubMed ID: 35416908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): a retrospective, observational, single-center, real-life study.
    Mastorino L; Burzi L; Frigatti G; Fazio A; Celoria V; Macagno N; Rosset F; Passerini SG; Roccuzzo G; Verrone A; Stroppiana E; Ortoncelli M; Dapavo P; Quaglino P; Ribero S
    Expert Opin Biol Ther; 2023; 23(9):929-936. PubMed ID: 37458181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis.
    Menter A; Bhutani T; Ehst B; Elewski B; Jacobson A
    Dermatol Ther (Heidelb); 2022 Jun; 12(6):1289-1302. PubMed ID: 35672564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
    Elewski BE; Blauvelt A; Gallo G; Wolf E; McKean-Matthews M; Burge R; Merola JF; Gottlieb AB; Guenther LC
    Dermatol Ther (Heidelb); 2022 Apr; 12(4):911-920. PubMed ID: 35279805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
    Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
    Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
    Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which Areas Are Still Left in Biologics Responsive Korean Patients with Moderate to Severe Plaque Psoriasis.
    Won SH; Shin BS; Bae KN; Son JH; Shin K; Kim HS; Ko HC; Kim MB; Kim BS
    Ann Dermatol; 2023 Feb; 35(1):6-10. PubMed ID: 36750453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.